Quotient receives final patent approval for its EnterionTM technology – The industry’s leading clinical technology for investigating drug absorption

1 May 2012 - Quotient Clinical, part of Quotient Bioresearch (“Quotient”) announced today that it has received approval of the final patent for its Enterion™ technology. This completes a portfolio of eight granted patents across North America and Europe, with a lifetime extending through to 2020.

The Enterion capsule has been developed to investigate the absorption of drugs from the gastrointestinal (GI) tract. It is a remote-controlled device that is capable of precisely delivering pharmaceutically relevant drug formulations (both liquids and solids) to specific sites within the GI tract. The information gained from these studies provides formulation scientists and clinical development teams with invaluable insights in order to guide the development of optimized drug products for oral administration.

Since its invention, Enterion has been used in over 120 clinical studies that have involved the dosing of over four thousand Enterion capsules to healthy volunteers at Quotient’s clinical facility in Nottingham, UK.

Mark Egerton, Managing Director, Quotient Clinical says: “Approval of this final patent represents a key milestone in our Enterion program. The technology has been in routine use for several years and reinforces our commitment to deliver innovative solutions for our customers. It is gratifying that Enterion has been deployed in development programs for many of the breakthrough medicines in the industry’s pipeline today.”

About Quotient Clinical
Quotient Clinical, part of Quotient Bioresearch, “Quotient”, has over 20 years’ experience delivering high quality data to provide innovative early drug development solutions to pharmaceutical and biotechnology clients worldwide, including 17 of the top 20 pharmaceutical companies. Our expertise in Exploratory Clinical Pharmacology, Drug Product Optimisation, and 14C Enabled Drug Development, underpinned by our unique Translational Pharmaceutics™ and Synthesis-to-Clinic™ delivery platforms, adds value to client programs. For further information or to discuss your specific needs about Enterion, please contact [email protected] or visit our website http://www.quotientbioresearch.com/clinical/drug-product-optimisation/enterion For general information, please contact: [email protected]

About Quotient Bioresearch
Quotient Bioresearch is a leading provider of early stage and specialist drug development services to life science clients worldwide. We provide tailored solutions for pharmaceutical, biotechnology and agrochemical clients, using state-of-the-art technologies underpinned by unparalleled medical, chemical and biological expertise. Our consultative, science-driven approach ensures the highest quality service to support and accelerate new product development. Our extensive range of capabilities spans Chemistry and Metabolism, Bioanalytical Sciences, and Clinical. These can be provided independently or integrated into bespoke work programmes. For additional information or to discuss your specific needs, contact us on [email protected] or visit www.quotientbioresearch.com

For further information please contact: Chrissie Walker
Account Director
Tel: +44(0)115 948 6900
E-mail: [email protected]